Eli Lilly says its weight loss pill orforglipron could win approval this year after a trial showed over 10% weight loss in ...

Eli Lilly said on Tuesday its experimental GLP-1 pill helped overweight adults with type 2 diabetes shed 10.5% of body weight ...

Meanwhile, access to Wegovy has improved slightly compared to last year, due in part to CVS Caremark’s decision to prefer Wegovy on its standard formulary.

In a study of more than 1,600 adults with type 2 diabetes, those who received the highest dose of orforglipron on average shed 10.5% of their weight.

(Corrects dateline to August 26) (Reuters) -Makers of weight-loss drugs are expected to rake in more than $150 billion in ...

The once-daily pill also helped 75 per cent of patients who received the highest dose of orforglipron lower their A1C level - ...

Eli Lilly shares gained Tuesday as results from a new study moved the drugmaker closer to applying for approval of its ...

Amgen's stock is up 13.5% in 2025, fueled by strong drug sales and new biosimilars, but looming competition and pricing ...

Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

The results of the ATTAIN-2 study, which involved people with obesity or overweight with type 2 diabetes, showed that the ...

The results of the ATTAIN-2 study, which involved people with obesity or overweight and type 2 diabetes, showed that the oral ...